Top Markets
Coin of the day
9 Meters Biopharma, Inc. 9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc.

NMTR
주식 순위 #40887
Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a... Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.
주가
$0.0169
마지막 동기화: 2023-08-21
시가총액
$66.40K
변동 (1일)
4.32%
변동 (1년)
0.00%
국가
US
거래 9 Meters Biopharma, Inc. (NMTR)

카테고리

9 Meters Biopharma, Inc. (NMTR)의 배당 수익률 기록
9 Meters Biopharma, Inc. (주식 심볼: NMTR)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
9 Meters Biopharma, Inc. (NMTR)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)